Autoimmunity significantly contributes to the pathogenesis of myocarditis, underscored by its
increased frequency in autoimmune diseases such as systemic lupus erythematosus and …

Immune checkpoint inhibitors (ICIs) are specialized monoclonal antibodies (mAbs) that
target immune checkpoints and their ligands, counteracting cancer cell-induced T-cell …

BACKGROUND: Immune checkpoint inhibitors (ICIs), antibodies targeting PD-1
(programmed cell death protein 1)/PD-L1 (programmed death-ligand 1) or CTLA4 (cytotoxic …

Immune checkpoint inhibitor (ICI) treatment has become an important therapeutic option for
various cancer types. Although the treatment is effective, ICI can overstimulate the patient's …

Immune-checkpoint inhibitors (ICIs) have revolutionized oncology, with nearly 50% of all
patients with cancer eligible for treatment with ICIs. However, patients on ICI therapy are at …

In addition to conventional chemoradiation and targeted cancer therapy, the use of immune
based therapies, specifically immune checkpoint inhibitors (ICIs) and chimeric antigen …

Immune checkpoint inhibitors (ICIs) have revolutionary effects on therapeutic strategies for
multiple malignancies. Their efficacy depends on their ability to reactivate the host immune …

Modulation of the heart's immune microenvironment is crucial for recovery after ischemic
events such as myocardial infarction (MI). Endothelial cells (ECs) can have immune …

The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started
with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy …

Immune checkpoint inhibitors have revolutionized cancer therapy and are increasingly used
to treat a wide range of oncological conditions, with dramatic benefits for many patients …